includes live biotherapeutics for Crohn’s disease, renal cell carcinoma, and methotrexate-associated adverse reactions, as well as small molecules for ulcerative colitis, autism spectrum disorder, and liver cancer. Lishan Biotech builds these candidates on proprietary Swarming technology, an intelligent microbial application platform that integrates multi-omics data with artificial intelligence, and a microbial-mimic small molecule platform. It also develops supporting tools such as a time-lapse incubation and imaging system for bacterial growth and motility studies. Through this integrated approach, Lishan Biotech focuses on advancing next-generation microbiome and small molecule therapeutics from discovery into clinical development.